140
+2.19%
Close of 9 Nov 2026, in JPY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Kidswell Bio
Its shares trade on Tokyo Stock Exchange under the ticker 4584.T. It has been listed since 30 November 2012. In the fiscal year to 31 March 2026, it reported revenue of ¥6.59bn and a net loss of ¥414.0m. At that date it held total assets of ¥6.09bn and shareholders' equity of ¥1.65bn.
Kidswell Bio Corp. engages in the research and development of biopharmaceutical products. The company is headquartered in Chuo-Ku, Tokyo-To. The company went IPO on 2012-11-30. The biosimilar business is engaged in the research, development and provision of filgrastim biosimilar products and pegfilgrastim biosimilar products for cancer, darbepoetin alfa biosimilar products for renal diseases, and ranibizumab biosimilar products for eye diseases. The new biopharmaceutical business is engaged in the research and development of anti-RAMP2 antibodies for cancer and eye diseases, as well as new antibodies. The new biotechnology business is engaged in the development of regenerative medicine products that utilize intracardiac stem cells for pediatric congenital heart diseases, and regenerative medicine products that utilize dental pulp stem cells for cleft lip and palate and intestinal ganglion cell deficiency diseases, as well as the joint research business with universities.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 30 Nov 2012
- Employees
- 41
- Website
- kidswellbio.com ↗
Leadership
Pay as last reported
- Mr. Shinya KurebayashiPresident, Chief Executive Officer, Chief Communication Officer, Executive Officer, Representative Director, since 2019
- Mr. Masayuki KawakamiChief Operating Officer, Executive Officer, Chief Development Officer, Chief Director of Development, Director, since 2018
- Mr. Yasuo SakaeExecutive Officer, Chief Administrative Officer, Chief Senior Director of Administration
- Mr. Yasuyuki MitaniExecutive Officer, Chief Director of Research, Director, since 2023
- Mr. Munechika SakabeExecutive Officer, Chief Director of Pharmaceutical, CMfO
- Mr. Norikazu EikiIndependent Director
- Ms. Sachiko NishiokaIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Kidswell Bio Corp's filgrastim biosimilar products for cancer treatment are in high demand.
- The company's pegfilgrastim biosimilar products address critical oncology needs globally.
- Ranibizumab biosimilar products for eye diseases show strong market potential in Japan.
Weaknesses
- The company's darbepoetin alfa biosimilar products for renal diseases face limited market penetration.
- Kidswell Bio Corp's anti-RAMP2 antibody research for cancer has limited clinical data available.
- Regenerative medicine products using dental pulp stem cells lack regulatory approvals in key markets.
Opportunities
- Expanding biosimilar offerings for cancer and renal diseases in the Japanese market.
- Collaborating with universities on regenerative medicine research for pediatric heart conditions.
- Growing demand for anti-RAMP2 antibodies in oncology and ophthalmology markets.
Threats
- Intense competition in the Japanese biopharmaceutical sector for biosimilar products.
- Regulatory delays for new biotechnology products in the Japanese healthcare system.
- High R&D costs for developing novel biopharmaceuticals in a competitive market.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.